7 Pulmonary Hypertension Headlines
1. 8 Red Flag Pulmonary Hypertension Symptoms
Unfortunately, pulmonary hypertension symptoms are generally not apparent early on in the onset of the disease, and this may be the case for years to come. However, as PH progresses, signs and symptoms of the disease will become apparent. Check out this list we’ve put together to discover more about eight red flag pulmonary hypertension symptoms you should be aware of.
Read more about it: http://bit.ly/1VpAiBY
2. 7 Medications to Treat Pulmonary Hypertension
According to the Mayo Clinic, discover which types of treatments or medications are available to help treat pulmonary hypertension. Read more about them here.
Read more about it: http://bit.ly/1MvjrMz
3. The 5 Different Classes of Pulmonary Hypertension
There are five different classes of pulmonary hypertension. For a detailed overview of each class, click on the link.
Read more about it: http://bit.ly/1VpBtBw
4. Hypothyroidism, a Thyroid Condition, Found in Almost Half of IPH Patients in Study
Researchers recently investigated the link between thyroid gland function and idiopathic pulmonary hypertension, finding subclinical hypothyroidism in almost half of patients observed. The study, “Assessment of Thyroid Function in Idiopathic Pulmonary Hypertension,” was published in the Research in Cardiovascular Medicine journal.
Read more about it: http://bit.ly/1VV7P7O
5. Pulmonary Rehab of Multiple Benefit to People with PH and Other Respiratory Diseases, Release Notes
Pulmonary rehabilitation has been shown to significantly improve the quality of life of those affected by lung diseases, including chronic obstructive pulmonary disease (COPD), interstitial pulmonary fibrosis (IPF), or pulmonary hypertension (PH), a University of Kentucky news release reported.
But what exactly is pulmonary rehabilitation?
Read more about it: http://bit.ly/1UwTqzo
6. Experimental PH Treatment, Ubenimex, Recognized as Orphan Drug by EMA in Advance of Clinical Study
Eiger BioPharmaceuticals recently announced that its protease inhibitor ubenimex has been granted Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of pulmonary arterial hypertension (PAH). The company will soon begin a Phase 2 clinical trial testing ubenimex in this patient group.
Read more about it: http://bit.ly/1qicIvB
7. Pediatric Cardiologist Marlene Rabinovitch Honored for Life’s Work on PH and Heart Disease Research
Marlene Rabinovitch, MD, a pediatric cardiology physician at Stanford Children’s Health and Lucile Packard Children’s Hospital Stanford, will be honored for her life’s work and present the 2016 J. Burns Amberson Lecture at the American Thoracic Society (ATS)’s Annual Meeting, which will take place in San Francisco on May 15.
About the Author
